Learn what the HHS 340B Drug Pricing Program is and what 340B hospitals are. The program allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals ...
The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...
AHA Board Chair Tina Freese Decker talks with AHA VP Aimee Kuhlman and Monument Health CEO Paulette Davidson about the benefits of the 340B program.
Senate HELP Committee Hearing Highlights Urgent Need to Reform 340B Program — Lawmakers Push for Transparency and Patient ...
CMS Finalizes 2.6% Payment Bump, Confirms Expansion of Site-Neutral Payments in 2026 OPPS Final Rule
CMS has issued a final OPPS rule for 2026, confirming a net 2.6% payment update, plans to expand site-neutral payment ...
Testimony from the GAO and CBO at a recent Senate hearing called for 340B reform, citing misaligned incentives due to spread ...
When the 340B drug pricing program was established in 1992, Congress intended for the program to help low-income and uninsured patients with their prescription drugs. The pharmaceutical companies ...
CMS outpatient rule finalizes site-neutral payments and cuts that increase financial strain on hospitals serving vulnerable populations, says AHA.
Oklahoma stepped in to save hospital profits with a new law, but a federal judge put it on hold while drugmakers argue its constitutionality.
HRSA experts from the agency’s Office of Pharmacy Affairs will oversee and handle disputes and claims related to overcharges for drugs, diversions of 340B drugs to ineligible patients, and duplicate ...
Two recent federal court cases signal new significant developments with respect to the 340B Drug Pricing Program. Specifically: (1) new federal district court litigation challenging a recent HRSA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback